This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.9/21/2007The proposed study will explore biological parameters as predictors of treatment response and explore changes in these measures associated with treatment response to 12 months of dialectical behavioral therapy (DBT), a treatment approach specifically targeted for improvement of emotional dysregulation in Borderline Personality Disorder (BPD). Assessments will include baseline, six and twelve month startle eye blink modulation (SEM) and baseline and post-treatment fMRI, each employing unpleasant and neutral words as emotional probes. SEM will provide an objective, nonverbal measure of affective processing and will be used both to predict treatment response and measure psychophysiologic change after DBT treatment. fMRI will be employed to examine pretreatment regional BOLD activation to the presentation of unpleasant versus neutral words or pictures and explore whether specific patterns of activation predict treatment response and whether clinical response is associated with specific patterns of activation.
Specific aims : (Protocol, p. 2) 1) To examine SEM in response to negative versus neutral BPD specific words in 36 BPD (ROI (PI Hazlett- funded study) and 26 normal controls (NC).Hypothesis: BPD subjects compared to NC will demonstrate an a) exaggerated startle response amplitude during unpleasant words, b) reduced affective modulation of the startle response to unpleasant words at later probe positions and c) reduced habituation to negative words. 2) To repeat the SEM assessment in response to negative and neutral BPD specific words in 17 BPD after six and twelve months of DBT. Parameters of SEM will include amplitude, time course, and habituation rate.Hypothesis: Improvement of BPD symptomatology as measured by changes in the ZAN-BPD at six and twelve month time points will significantly correlate with a) an attenuation of the exaggerated startle response amplitude during unpleasant words, b) greater affective modulation of unpleasant words at later probe positions c) increased habituation of negative emotion across trials.3) To examine differences in baseline fMRI BOLD response magnitude, time course and habituation in PFC and amygdala to negative and neutral BPD-specific words to predict treatment response, as measured by changes in the ZAN-BPD, to a 12 month DBT trial.Hypothesis: DBT treatment response as measured by ZAN-BPD change scores will significantly correlate with baseline fMRI BOLD activation (unpleasant- neutral word conditions) in PFC and significantly inversely correlate with baseline fMRI BOLD activation in the amygdala. Additionally, DBT treatment response will significantly correlate with baseline habituation response as demonstrated by less amygdala activation with repeated exposure to negative words over time. Exploratory hypothesis:4) To repeat fMRI after 12 months DBT in 17 BPD to examine differences (post-pre) fMRI BOLD response magnitude, time course and habituation in PFC and amygdala to negative and neutral BPD-specific words and correlate with treatment response. Results will be compared to fMRI findings in 16 normal controls at baseline and 12 months.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000071-45
Application #
7718199
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2008-03-01
Project End
2009-02-28
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
45
Fiscal Year
2008
Total Cost
$1,712
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451
Kattan, Meyer; Bacharier, Leonard B; O'Connor, George T et al. (2018) Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. J Allergy Clin Immunol Pract 6:1596-1603.e6
Coplan, Jeremy D; Webler, Ryan; Gopinath, Srinath et al. (2018) Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. J Affect Disord 229:1-13
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866
Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671
Chen, Teresa K; Appel, Lawrence J; Grams, Morgan E et al. (2017) APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension). Arterioscler Thromb Vasc Biol 37:1765-1769
Ku, Elaine; Gassman, Jennifer; Appel, Lawrence J et al. (2017) BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol 28:671-677
Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Gern, James E; Calatroni, Agustin; Jaffee, Katy F et al. (2017) Patterns of immune development in urban preschoolers with recurrent wheeze and/or atopy. J Allergy Clin Immunol 140:836-844.e7
Abdallah, Chadi G; Jackowski, Andrea; Salas, Ramiro et al. (2017) The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology 42:1739-1746

Showing the most recent 10 out of 869 publications